Lack of VEGFA/KDR signaling in conventional renal cell carcinoma explains the low efficacy of target therapy and frequent adverse events
It is acknowledged that conventional renal cell carcinoma (cRCC), which makes up 85% of renal malignancies, is a highly vascular tumor. Humanized monoclonal antibodies were developed to inhibit tumor neo-angiogenesis, which is driven by VEGFA/KDR signaling. The results largely met our expectations,...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
4 July 2024
|
| In: |
International journal of molecular sciences
Year: 2024, Jahrgang: 25, Heft: 13, Pages: 1-9 |
| ISSN: | 1422-0067 |
| DOI: | 10.3390/ijms25137359 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.3390/ijms25137359 Verlag, kostenfrei, Volltext: https://www.mdpi.com/1422-0067/25/13/7359 
|
| Verfasserangaben: | Lehel Peterfi, Maria V. Yusenko, Gyula Kovacs and Tamas Beothe |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1915134900 | ||
| 003 | DE-627 | ||
| 005 | 20250716223128.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250120s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/ijms25137359 |2 doi | |
| 035 | |a (DE-627)1915134900 | ||
| 035 | |a (DE-599)KXP1915134900 | ||
| 035 | |a (OCoLC)1528016474 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Peterfi, Lehel |e VerfasserIn |0 (DE-588)1187980692 |0 (DE-627)1666944742 |4 aut | |
| 245 | 1 | 0 | |a Lack of VEGFA/KDR signaling in conventional renal cell carcinoma explains the low efficacy of target therapy and frequent adverse events |c Lehel Peterfi, Maria V. Yusenko, Gyula Kovacs and Tamas Beothe |
| 264 | 1 | |c 4 July 2024 | |
| 300 | |b Illustrationen | ||
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 20.01.2025 | ||
| 520 | |a It is acknowledged that conventional renal cell carcinoma (cRCC), which makes up 85% of renal malignancies, is a highly vascular tumor. Humanized monoclonal antibodies were developed to inhibit tumor neo-angiogenesis, which is driven by VEGFA/KDR signaling. The results largely met our expectations, and in several cases, adverse events occurred. Our study aimed to analyze the expression of VEGFA and its receptor KDR by immunohistochemistry in tissue multi-array containing 811 cRCC and find a correlation between VEGFA/KDR signaling and new vessel formation. None of the 811 cRCC displayed VEGFA-positive immunostaining. However, each glomerulus in normal kidney showed VEGFA-positive endothelial cells. KDR expression in endothelial meshwork was found in only 9% of cRCC, whereas 2% of the cRCC displayed positive KDR reaction in the cytoplasm of tumor cells. Our results disclose the involvement of VEGFA/KDR signaling in the neo-vascularization of cRCC and explain the frequent resistance to drugs targeting the VEGFA/KDR signaling and the high frequency of adverse events. | ||
| 650 | 4 | |a adverse events | |
| 650 | 4 | |a immunohistochemistry | |
| 650 | 4 | |a KDR | |
| 650 | 4 | |a renal cell carcinoma | |
| 650 | 4 | |a VEGFA | |
| 700 | 1 | |a Yusenko, Maria V. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kovacs, Gyula |e VerfasserIn |0 (DE-588)1081747579 |0 (DE-627)846587424 |0 (DE-576)454756399 |4 aut | |
| 700 | 1 | |a Beothe, Tamas |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of molecular sciences |d Basel : Molecular Diversity Preservation International, 2000 |g 25(2024), 13, Artikel-ID 7359, Seite 1-9 |h Online-Ressource |w (DE-627)316340715 |w (DE-600)2019364-6 |w (DE-576)281194653 |x 1422-0067 |7 nnas |a Lack of VEGFA/KDR signaling in conventional renal cell carcinoma explains the low efficacy of target therapy and frequent adverse events |
| 773 | 1 | 8 | |g volume:25 |g year:2024 |g number:13 |g elocationid:7359 |g pages:1-9 |g extent:9 |a Lack of VEGFA/KDR signaling in conventional renal cell carcinoma explains the low efficacy of target therapy and frequent adverse events |
| 856 | 4 | 0 | |u https://doi.org/10.3390/ijms25137359 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.mdpi.com/1422-0067/25/13/7359 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20250120 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 1081747579 |a Kovacs, Gyula |m 1081747579:Kovacs, Gyula |d 50000 |e 50000PK1081747579 |k 0/50000/ |p 3 | ||
| 999 | |a KXP-PPN1915134900 |e 4654187243 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"9 S.","noteIll":"Illustrationen"}],"relHost":[{"language":["eng"],"recId":"316340715","disp":"Lack of VEGFA/KDR signaling in conventional renal cell carcinoma explains the low efficacy of target therapy and frequent adverse eventsInternational journal of molecular sciences","note":["Gesehen am 17.09.20"],"type":{"bibl":"periodical","media":"Online-Ressource"},"titleAlt":[{"title":"IJMS"}],"part":{"issue":"13","pages":"1-9","year":"2024","extent":"9","volume":"25","text":"25(2024), 13, Artikel-ID 7359, Seite 1-9"},"pubHistory":["1.2000 -"],"title":[{"title_sort":"International journal of molecular sciences","title":"International journal of molecular sciences"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["1422-0067","1661-6596"],"eki":["316340715"],"zdb":["2019364-6"]},"origin":[{"publisherPlace":"Basel","dateIssuedDisp":"2000-","dateIssuedKey":"2000","publisher":"Molecular Diversity Preservation International"}]}],"name":{"displayForm":["Lehel Peterfi, Maria V. Yusenko, Gyula Kovacs and Tamas Beothe"]},"origin":[{"dateIssuedKey":"2024","dateIssuedDisp":"4 July 2024"}],"id":{"doi":["10.3390/ijms25137359"],"eki":["1915134900"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 20.01.2025"],"language":["eng"],"recId":"1915134900","person":[{"roleDisplay":"VerfasserIn","display":"Peterfi, Lehel","role":"aut","family":"Peterfi","given":"Lehel"},{"roleDisplay":"VerfasserIn","display":"Yusenko, Maria V.","role":"aut","family":"Yusenko","given":"Maria V."},{"family":"Kovacs","given":"Gyula","roleDisplay":"VerfasserIn","display":"Kovacs, Gyula","role":"aut"},{"given":"Tamas","family":"Beothe","role":"aut","display":"Beothe, Tamas","roleDisplay":"VerfasserIn"}],"title":[{"title":"Lack of VEGFA/KDR signaling in conventional renal cell carcinoma explains the low efficacy of target therapy and frequent adverse events","title_sort":"Lack of VEGFA/KDR signaling in conventional renal cell carcinoma explains the low efficacy of target therapy and frequent adverse events"}]} | ||
| SRT | |a PETERFILEHLACKOFVEGF4202 | ||